AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31685553 — intervention group
Group type: COMPARATOR
Intervention: Placebo followed by ixekizumab (PBO/IXE) in COAST-W
Number of subjects: 657
Study 31096515 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg esomeprazole
Number of subjects: 197
Study 31096515 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg esomeprazole
Number of subjects: 197
Study 26882061 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dilute epinephrine (DE) 1% with lidocaine 1:100,000
Number of subjects: 41
Study 26882061 — intervention group
Group type: COMPARATOR
Intervention: Topical phenylephrine 2.5%
Number of subjects: 41
Study 25534490 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil liposomal preparation
Number of subjects: 32
Study 25534490 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 32
Study 23760871 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 % imidacloprid/4.5 % flumethrin collar (Seresto®, Bayer)
Number of subjects: 20
Study 23760871 — intervention group
Group type: COMPARATOR
Intervention: Non-treated control group
Number of subjects: 20
Study 21462690 — intervention group
Group type: EXPERIMENTAL
Intervention: Coach approach intervention
Number of subjects: 137
Study 19397561 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema workshop
Number of subjects: 99
Study 19397561 — intervention group
Group type: COMPARATOR
Intervention: Dermatologist-led clinic
Number of subjects: 99
Study 16453184 — intervention group
Group type: EXPERIMENTAL
Intervention: Tracing method
Number of subjects: 24
Study 16453184 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 24
Study 15365430 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-energy all-purpose (ME) collimator
Number of subjects: 15
Study 15365430 — intervention group
Group type: COMPARATOR
Intervention: Low-energy all-purpose (LEAP) collimator
Number of subjects: 15
Study 11407869 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplementation for 10 days
Number of subjects: 17
Study 11407869 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 malnourished elderly subjects)
Number of subjects: 17
Study 8988886 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary bypass surgery
Number of subjects: 934
Study 8988886 — intervention group
Group type: COMPARATOR
Intervention: Coronary angioplasty
Number of subjects: 934
Study 8358112 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroform/methanol (CM; 2:1)
Number of subjects: 16
Study 8358112 — intervention group
Group type: EXPERIMENTAL
Intervention: Ether/acetone (EA; 1:1)
Number of subjects: 16
Study 8358112 — intervention group
Group type: COMPARATOR
Intervention: Control site
Number of subjects: 16
Study 3653758 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine 2 mg
Number of subjects: 10
Study 3653758 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine 3 mg
Number of subjects: 10
Study 3653758 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine 5 mg
Number of subjects: 10
Study 3653758 — intervention group
Group type: COMPARATOR
Intervention: Pirenzepine 50 mg
Number of subjects: 10
Study 3653758 — intervention group
Group type: EXPERIMENTAL
Intervention: Telenzepine
Number of subjects: 10
Study 31957889 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated assay (Galileo NEO, Immucor)
Number of subjects: 54
Study 31957889 — intervention group
Group type: COMPARATOR
Intervention: Manual gel testing
Number of subjects: 54
Study 29721623 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational material delivered by postal mail
Number of subjects: 54
Study 29721623 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational material delivered by patient choice (postal mail, email, or text messaging)
Number of subjects: 54
Study 29721623 — intervention group
Group type: COMPARATOR
Intervention: Control group without educational material
Number of subjects: 54
Study 26912491 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg DHA/d
Number of subjects: 654
Study 26912491 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study 25081652 — intervention group
Group type: EXPERIMENTAL
Intervention: Home mechanical ventilation (HMV)
Number of subjects: 77
Study 25081652 — intervention group
Group type: COMPARATOR
Intervention: Hospital initiation of mechanical ventilation
Number of subjects: 77
Study 22251828 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurocognitive habilitation therapy (group therapy intervention for foster and adoptive caregivers and their children)
Number of subjects: 78
Study 22251828 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 78
Study 21077522 — intervention group
Group type: EXPERIMENTAL
Intervention: New method for chorion villus sampling (group 2)
Number of subjects: 0
Study 21077522 — intervention group
Group type: COMPARATOR
Intervention: Traditional single needle technique (group 1)
Number of subjects: 0
Study 18680574 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple imputation procedures (last value carried forward, next value carried backward, last-and-next)
Number of subjects: 0
Study 18680574 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothesis test and logistic regression approaches
Number of subjects: 0
Study 15728081 — intervention group
Group type: EXPERIMENTAL
Intervention: IV clonidine 1 microg/kg (group IC)
Number of subjects: 36
Study 15728081 — intervention group
Group type: COMPARATOR
Intervention: IV saline (group L)
Number of subjects: 36
Study 15728081 — intervention group
Group type: EXPERIMENTAL
Intervention: IV saline and PCB with clonidine 1 microg/kg (group C)
Number of subjects: 36
Study 15728081 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 36
Study 12850874 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse practitioner ‐ physician team
Number of subjects: 157
Study 12850874 — intervention group
Group type: COMPARATOR
Intervention: Physician alone
Number of subjects: 157
Study 10541912 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) at a frequency of 4 Hz (1.0 ms(‐2) rms) for 10 minutes
Number of subjects: 10
Study 10541912 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 10
Study 10541912 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with anticholinergic (scopolamine) and alpha-adrenergic blocking agents (prazosin)
Number of subjects: 10
Study 10541912 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with beta-adrenergic blocking agent (propranolol)
Number of subjects: 10
Study 9084534 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 3 mg/kg/h after 0.3 mg/kg bolus injection (Group A)
Number of subjects: 45
Study 9084534 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion at 4 mg/kg/h after 0.4 mg/kg bolus injection (Group B)
Number of subjects: 45
Study 9084534 — intervention group
Group type: COMPARATOR
Intervention: Propofol infusion at 5 mg/kg/h after 0.5 mg/kg bolus injection (Group C)
Number of subjects: 45
Study 1879784 — intervention group
Group type: EXPERIMENTAL
Intervention: Materna Tsimchit
Number of subjects: 45
Study 1879784 — intervention group
Group type: COMPARATOR
Intervention: Isomil
Number of subjects: 45
Study 6980404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (4.5 g/day)
Number of subjects: 12
Study 6980404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6980404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 12
Study 6980404 — intervention group
Group type: COMPARATOR
Intervention: Tranexamic acid and Placebo
Number of subjects: 12
Study 30580469 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (E)
Number of subjects: 39
Study 29136187 — intervention group
Group type: EXPERIMENTAL
Intervention: Single early intravesical instillation of pirarubicin
Number of subjects: 310
Study 29136187 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 310
Study 26948548 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) technique
Number of subjects: 105
Study 26948548 — intervention group
Group type: COMPARATOR
Intervention: Single-bundle (SB) technique
Number of subjects: 105
Study 25124257 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic workplace
Number of subjects: 40
Study 25124257 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 40
Study 22516265 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaseous cryotherapy (GC)
Number of subjects: 66
Study 22516265 — intervention group
Group type: COMPARATOR
Intervention: Cold pack
Number of subjects: 66
Study 22516265 — intervention group
Group type: COMPARATOR
Intervention: Cryocuff
Number of subjects: 66
Study 20736192 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate or early percutaneous coronary intervention (PCI) after fibrinolysis
Number of subjects: 3325
Study 20736192 — intervention group
Group type: COMPARATOR
Intervention: Deferred PCI or ischaemia-guided management
Number of subjects: 3325
Study 18042518 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week moderate exercise training (60% heart rate reserve), 25-minute cycling followed by 10-minute warm-up/cool-down, 3 times a week
Number of subjects: 20
Study 18042518 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 matched sedentary subjects) without exercise
Number of subjects: 20
Study 16318970 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfreezing needles (‐14 degrees C)
Number of subjects: 62
Study 16318970 — intervention group
Group type: COMPARATOR
Intervention: Room temperature needles (20‐22 degrees C)
Number of subjects: 62
Study 12417543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 11
Study 12417543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 12417543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine + Metoprolol
Number of subjects: 11
Study 10379020 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (5000 IU intramuscularly three times per week for four weeks)
Number of subjects: 807
Study 10379020 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 807
Study 10379020 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (control group)
Number of subjects: 807
Study 8590162 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 848
Study 8590162 — intervention group
Group type: COMPARATOR
Intervention: H2-receptor blockers (ranitidine or famotidine)
Number of subjects: 848
Study 8590162 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, famotidine, nizatidine, cimetidine, or sucralfate
Number of subjects: 848
Study 1838397 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-hexakis 2-methoxy isobutyl isonitrile (99mTc-MIBI)
Number of subjects: 464
Study 7067923 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat action tablet containing 1 mg of azatadine maleate and 60 mg of d-pseudoephedrine sulfate
Number of subjects: 0
Study 7067923 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablet of 60 mg of d-pseudoephedrine sulfate
Number of subjects: 0
Study 7067923 — intervention group
Group type: COMPARATOR
Intervention: Conventional tablet of 1 mg of azatadine maleate
Number of subjects: 0
Study 28891024 — intervention group
Group type: EXPERIMENTAL
Intervention: HFD supplemented with 0.04% RSV
Number of subjects: 3
Study 28891024 — intervention group
Group type: EXPERIMENTAL
Intervention: HFD supplemented with 0.36% RSV
Number of subjects: 3
Study 28891024 — intervention group
Group type: EXPERIMENTAL
Intervention: HFD supplemented with 1.08% RSV
Number of subjects: 3
Study 28891024 — intervention group
Group type: COMPARATOR
Intervention: Normal fat diet (NFD, 5% fat, w/w)
Number of subjects: 3
Study 28891024 — intervention group
Group type: COMPARATOR
Intervention: HFD (11% fat)
Number of subjects: 3
Study 27228369 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovulation induction treatment
Number of subjects: 748
Study 27228369 — intervention group
Group type: EXPERIMENTAL
Intervention: Antral follicle count
Number of subjects: 748
Study 26218723 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypodium leucotomos (PLE) supplementation after photodynamic therapy (PDT)
Number of subjects: 34
Study 26218723 — intervention group
Group type: COMPARATOR
Intervention: Photodynamic therapy (PDT) alone
Number of subjects: 34
Study 23878827 — intervention group
Group type: EXPERIMENTAL
Intervention: Herculite Précis (M1)
Number of subjects: 8
Study 23878827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tertic N‐Ceram (M2)
Number of subjects: 8
Study 23878827 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek Z350 (M3)
Number of subjects: 8
Study 23878827 — intervention group
Group type: EXPERIMENTAL
Intervention: Charisma Opal (M4)
Number of subjects: 8
Study 20376059 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin (0.5 IU kg⁻¹ h⁻¹ in TPN solutions)
Number of subjects: 246
Study 20376059 — intervention group
Group type: COMPARATOR
Intervention: No heparin (TPN fluids without heparin)
Number of subjects: 246
Study 19034975 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose acetaminophen and NSAIDs ingestion (group I)
Number of subjects: 80
Study 19034975 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple NSAIDs ingestion (group Ic)
Number of subjects: 80
Study 19034975 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs ingestion (group Ib)
Number of subjects: 80
Study 16769016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 190
Study 16769016 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal slingplasty (IVS)
Number of subjects: 190
Study 12707697 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-coated components
Number of subjects: 0
Study 12707697 — intervention group
Group type: COMPARATOR
Intervention: Non-HA-coated components
Number of subjects: 0
Study 11142412 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical DFMO ointment (10% w/w) applied twice daily for 6 months
Number of subjects: 48
Study 11142412 — intervention group
Group type: COMPARATOR
Intervention: Placebo hydrophilic ointment applied twice daily for 6 months
Number of subjects: 48
Study 9066044 — intervention group
Group type: EXPERIMENTAL
Intervention: TryIPV
Number of subjects: 0
Study 9066044 — intervention group
Group type: COMPARATOR
Intervention: Regular E-IPV
Number of subjects: 0
Study 8104062 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate 60 mg (single im injection)
Number of subjects: 44
Study 8104062 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide 200 micrograms bid (aerosol spray)
Number of subjects: 44
Study 8104062 — intervention group
Group type: COMPARATOR
Intervention: Terfenadine 60 mg daily (tablets)
Number of subjects: 44
Study 3542441 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) 0.5 mg qid
Number of subjects: 0
Study 3542441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30041598 — intervention group
Group type: EXPERIMENTAL
Intervention: Connection to Health (CTH) program
Number of subjects: 0
Study 30041598 — intervention group
Group type: EXPERIMENTAL
Intervention: Connection to Health (CTH) program plus practice facilitation
Number of subjects: 0
Study 30041598 — intervention group
Group type: COMPARATOR
Intervention: SMS academic detailing educational intervention
Number of subjects: 0
Study 28073198 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of prostatic calculi (PC) in peripheral zone (PZ) during TRUS
Number of subjects: 664
Study 28073198 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of prostatic calculi (PC) in transitional zone (TZ) and central zone (CZ) during TRUS
Number of subjects: 664
Study 28073198 — intervention group
Group type: COMPARATOR
Intervention: Patients with prostate cancer (CaP)
Number of subjects: 664
Study 24351403 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no active treatment)
Number of subjects: 274
Study 23408280 — intervention group
Group type: EXPERIMENTAL
Intervention: Familias Unidas intervention
Number of subjects: 213
Study 21114343 — intervention group
Group type: EXPERIMENTAL
Intervention: 4Rs Program
Number of subjects: 942
Study 18249325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (loading dose of 2 x 10(6) KIU followed by continuous infusion at 5 x 10(5) KIU/h until skin closure)
Number of subjects: 50
Study 18249325 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 50
Study 18249325 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 16830217 — intervention group
Group type: EXPERIMENTAL
Intervention: PPH33-01
Number of subjects: 60
Study 16830217 — intervention group
Group type: EXPERIMENTAL
Intervention: PPH33-03
Number of subjects: 60
Study 12756219 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 375
Study 12756219 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 375
Study 10781982 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin (1.5 g daily)
Number of subjects: 30000
Study 10781982 — intervention group
Group type: COMPARATOR
Intervention: Meropenem (3 g daily)
Number of subjects: 30000
Study 8692425 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional MRI at 1.5 T
Number of subjects: 23
Study 8692425 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional MRI at 0.5 T
Number of subjects: 23
Study 8692425 — intervention group
Group type: COMPARATOR
Intervention: CT myelography
Number of subjects: 23
Study 1332520 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom giveaway program
Number of subjects: 103
Study 2866715 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% betaxolol, treated twice daily for six weeks
Number of subjects: 19
Study 2866715 — intervention group
Group type: COMPARATOR
Intervention: Placebo, treated twice daily for six weeks
Number of subjects: 19
Study 31330882 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensively hydrolyzed protein (EHF) formula
Number of subjects: 0
Study 31330882 — intervention group
Group type: COMPARATOR
Intervention: Intact protein premature formula (IPF)
Number of subjects: 0
Study 31330882 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EHF and IPF formulas
Number of subjects: 0
Study 29137956 — intervention group
Group type: EXPERIMENTAL
Intervention: 19-Gy high-dose-rate brachytherapy (HDR-BT)
Number of subjects: 87
Study 27460266 — intervention group
Group type: EXPERIMENTAL
Intervention: 2200 IU/day vitamin D3 supplementation
Number of subjects: 128
Study 27460266 — intervention group
Group type: EXPERIMENTAL
Intervention: 1100 IU/day vitamin D3 supplementation
Number of subjects: 128
Study 27460266 — intervention group
Group type: COMPARATOR
Intervention: No vitamin D supplementation (sufficient group)
Number of subjects: 128
Study 24664858 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg of caffeine per kg of body mass)
Number of subjects: 15
Study 22453250 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity Exercise (LI, 30% HR reserve), n = 23
Number of subjects: 49
Study 22453250 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Exercise (MI, 70% HR reserve), n = 26
Number of subjects: 49
Study 22453250 — intervention group
Group type: COMPARATOR
Intervention: Control group (historical control, n = 45)
Number of subjects: 49
Study 19889807 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume-enriched, low-glycemic index diet (250 g/d, GI 38)
Number of subjects: 64
Study 19889807 — intervention group
Group type: COMPARATOR
Intervention: Healthy American diet (high-GI, GI 69)
Number of subjects: 64
Study 19889807 — intervention group
Group type: EXPERIMENTAL
Intervention: Legume-enriched, low-glycemic index diet
Number of subjects: 64
Study 19889807 — intervention group
Group type: COMPARATOR
Intervention: Healthy American diet
Number of subjects: 64
Study 18947357 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconscious thought (participants were distracted while holding the goal of solving the RAT items)
Number of subjects: 0
Study 18947357 — intervention group
Group type: COMPARATOR
Intervention: Conscious thought
Number of subjects: 0
Study 16952782 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 1707
Study 16952782 — intervention group
Group type: COMPARATOR
Intervention: No ACE inhibitors
Number of subjects: 1707
Study 12672185 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (Enbrel®) administered subcutaneously twice weekly
Number of subjects: 1128
Study 10827665 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfoamwave (study mattress)
Number of subjects: 100
Study 10827665 — intervention group
Group type: COMPARATOR
Intervention: Transfoam (standard hospital mattress)
Number of subjects: 100
Study 8861666 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-day head-down tilt (HDT; -6 degrees)
Number of subjects: 8
Study 8861666 — intervention group
Group type: COMPARATOR
Intervention: 4-day confinement
Number of subjects: 8
Study 1516500 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning NPH insulin (22 +/- 1 IU) plus 3.5 mg glibenclamide twice a day
Number of subjects: 24
Study 1516500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime NPH insulin (22 +/- 1 IU) plus 3.5 mg glibenclamide twice a day
Number of subjects: 24
Study 1516500 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime NPH insulin
Number of subjects: 24
Study 1516500 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning NPH insulin
Number of subjects: 24
Study 6704285 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 60
Study 6704285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 31306167 — intervention group
Group type: EXPERIMENTAL
Intervention: DMPA-IM
Number of subjects: 95
Study 31306167 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone enanthate
Number of subjects: 95
Study 31306167 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants
Number of subjects: 95
Study 31306167 — intervention group
Group type: EXPERIMENTAL
Intervention: IUD
Number of subjects: 95
Study 31306167 — intervention group
Group type: COMPARATOR
Intervention: Combined hormonal methods (DMPA-IM, norethisterone enanthate, implants)
Number of subjects: 95
Study 28296510 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary outpatient rehabilitation
Number of subjects: 151